Stephen Anthony Boorjian

Q: What Schools Are Affiliated With Stephen Anthony Boorjian

Stephen Anthony Boorjian is affiliated with the following schools: University of Kentucky, Michigan State University, Thomas Jefferson University

Stephen Anthony Boorjian's AcademicInfluence.com Rankings

Philosophy

#6302

World Rank

#9316

Historical Rank

Logic

#3478

World Rank

#4642

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Stephen Anthony Boorjian's Degrees

Doctorate Medicine University of Minnesota

Why Is Stephen Anthony Boorjian Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stephen Anthony Boorjian's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. (2016) (915)
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. (2008) (672)
Epidemiology of Renal Cell Carcinoma. (2019) (548)
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. (2016) (426)
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. (2004) (359)
Survival after complete surgical resection of multiple metastases from renal cell carcinoma (2011) (347)
Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. (2015) (345)
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. (2010) (344)
Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. (2011) (311)
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. (2007) (289)
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. (2011) (264)
Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer (2011) (258)
T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival (2008) (249)
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer‐specific and all‐cause mortality (2014) (237)
Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma (2008) (235)
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. (2008) (233)
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. (2011) (233)
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (230)
Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. (2012) (230)
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. (2014) (224)
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. (2012) (219)
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. (2010) (216)
Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder (2005) (201)
Efficiency, satisfaction, and costs for remote video visits following radical prostatectomy: a randomized controlled trial. (2015) (199)
Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. (2012) (194)
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance (2009) (192)
Urinary cytology has a poor performance for predicting invasive or high‐grade upper‐tract urothelial carcinoma (2011) (184)
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. (2012) (181)
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. (2018) (180)
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. (2013) (176)
Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. (2013) (166)
Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. (2014) (164)
Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. (2004) (155)
High-risk prostate cancer: from definition to contemporary management. (2012) (146)
Robot-assisted partial nephrectomy: a large single-institutional experience. (2010) (139)
Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. (2014) (135)
Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. (2013) (132)
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. (2010) (127)
Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. (2014) (124)
Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. (2014) (123)
The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. (2012) (122)
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. (2017) (119)
Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology (2005) (119)
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. (2019) (117)
Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. (2014) (117)
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. (2013) (115)
The impact of obstructive interval and sperm granuloma on outcome of vasectomy reversal. (2004) (112)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. (2020) (110)
The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. (2014) (109)
Outcomes following partial nephrectomy by tumor size. (2008) (106)
The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. (2007) (105)
Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. (2007) (104)
Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. (2013) (104)
Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. (2016) (104)
Risk factors and outcomes of urethral recurrence following radical cystectomy. (2011) (102)
Partial nephrectomy for renal masses ≥7 cm: technical, oncological and functional outcomes (2012) (102)
Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta‐Analysis (2017) (101)
Renal cell carcinoma: vena caval involvement (2007) (101)
Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. (2019) (99)
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. (2007) (98)
Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. (2014) (97)
Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. (2014) (97)
Overcoming Drug Resistance and Treating Advanced Prostate Cancer (2012) (97)
Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. (2016) (95)
Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. (2018) (95)
Long-term renal function outcomes after radical cystectomy. (2014) (95)
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. (2012) (95)
A Novel Grading System for Clear Cell Renal Cell Carcinoma Incorporating Tumor Necrosis (2013) (94)
Predicting survival of patients with node-positive prostate cancer following multimodal treatment. (2014) (91)
Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. (2011) (90)
Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. (2013) (90)
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. (2008) (89)
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. (2012) (89)
Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers (2008) (88)
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. (2017) (88)
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. (2013) (86)
Survivorship and improving quality of life in men with prostate cancer. (2015) (86)
The Microbiome and Genitourinary Cancer: A Collaborative Review. (2019) (84)
Radiation therapy after radical prostatectomy: impact on metastasis and survival. (2009) (83)
Microhematuria: AUA/SUFU Guideline. (2020) (81)
Guideline of guidelines: asymptomatic microscopic haematuria (2018) (81)
Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. (2017) (81)
A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. (2018) (80)
Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. (2015) (77)
The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. (2018) (76)
Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. (2017) (75)
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. (2008) (73)
Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases (2009) (72)
A novel prognostic model for patients with sarcomatoid renal cell carcinoma (2015) (72)
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. (2013) (72)
High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. (2012) (71)
The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta‐analysis (2018) (69)
Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome (2014) (68)
Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. (2014) (68)
Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. (2017) (68)
Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? (2014) (67)
20‐year survival after radical prostatectomy as initial treatment for cT3 prostate cancer (2012) (67)
Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. (2005) (67)
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. (2011) (67)
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. (2011) (66)
Cystectomy for refractory hemorrhagic cystitis: contemporary etiology, presentation and outcomes. (2015) (66)
Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. (2014) (65)
A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. (2011) (65)
Functional and oncological outcomes after orthotopic neobladder reconstruction in women (2008) (65)
Contemporary trends of in‐hospital complications and mortality for radical cystectomy (2012) (65)
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. (2008) (65)
Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. (2017) (65)
Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. (2015) (64)
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. (2016) (64)
Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. (2014) (64)
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. (2015) (64)
Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? (2006) (63)
The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. (2014) (63)
Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. (2017) (62)
Microencapsulation of Leydig cells: a system for testosterone supplementation. (2003) (62)
The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. (2013) (61)
Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines (2016) (61)
Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. (2014) (61)
Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. (2015) (61)
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy (2009) (59)
Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis (2012) (59)
Eligibility for neoadjuvant/adjuvant cisplatin‐based chemotherapy among radical cystectomy patients (2014) (57)
Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus (2015) (57)
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. (2008) (57)
Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. (2017) (57)
Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma (2018) (57)
High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. (2014) (57)
Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. (2019) (56)
Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. (2019) (56)
ABLATE: a renal ablation planning algorithm. (2014) (55)
Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. (2017) (55)
Hospitalization costs for radical prostatectomy attributable to robotic surgery. (2013) (55)
The effect of gender on response to bacillus Calmette‐Guérin therapy for patients with non‐muscle‐invasive urothelial carcinoma of the bladder (2010) (54)
The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. (2009) (54)
Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma (2019) (54)
Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. (2018) (53)
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? (2013) (52)
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. (2018) (52)
Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? (2005) (51)
Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. (2008) (51)
Impact of peri‐operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder (2014) (51)
Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. (2013) (50)
Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. (2011) (50)
Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. (2017) (50)
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy (2011) (50)
Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. (2018) (48)
The impact of perioperative blood transfusion on survival after nephrectomy for non‐metastatic renal cell carcinoma (RCC) (2014) (48)
Population‐based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer (2013) (48)
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. (2018) (46)
Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. (2008) (45)
Renal function outcomes in patients treated with partial nephrectomy versus percutaneous ablation for renal tumors in a solitary kidney. (2011) (45)
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 (2021) (44)
Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi‐Institutional Analysis (2017) (43)
Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? (2011) (43)
Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? (2016) (42)
Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer (2011) (42)
Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. (2013) (42)
A single-institution experience in image-guided thermal ablation of adrenal gland metastases. (2014) (42)
Right laparoscopic live donor nephrectomy: a single institution experience (2004) (41)
Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. (2015) (40)
The impact of clinical stage on prostate cancer survival following radical prostatectomy. (2013) (40)
Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. (2016) (40)
Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma (2007) (39)
Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. (2014) (38)
Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis (2017) (37)
Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. (2013) (37)
Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. (2008) (37)
The relationship of postoperative complications with in‐hospital outcomes and costs after renal surgery for kidney cancer (2013) (36)
Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. (2011) (36)
Expression of cyclin d1 and its association with disease characteristics in bladder cancer. (2013) (36)
The association of tumor volume with mortality following radical prostatectomy (2014) (36)
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. (2019) (36)
Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram (2012) (36)
Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. (2015) (35)
Impact of prostate‐specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8–10 cancers (2008) (35)
Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. (2014) (35)
Practice‐setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons (2013) (35)
Long‐term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder (2015) (35)
Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis. (2018) (35)
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort (2011) (35)
Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle‐invasive bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy and radical cystectomy: a single‐centre experience (2019) (34)
Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. (2020) (34)
Complete Surgical Metastasectomy for Renal Cell Carcinoma in the Post-cytokine Era. (2020) (34)
Bladder cancer, version 3.2020 (2020) (34)
Comparative impact of continent and incontinent urinary diversion on long‐term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a (2015) (33)
Characterization of perioperative infection risk among patients undergoing radical cystectomy: Results from the national surgical quality improvement program. (2016) (33)
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers (2011) (33)
The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. (2015) (32)
The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass (2018) (32)
Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. (2014) (32)
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. (2017) (31)
Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. (2021) (31)
Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear‐cell renal cell carcinoma (2018) (30)
The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis (2017) (30)
Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion During Open Radical Cystectomy. (2016) (30)
The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. (2013) (30)
Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. (2016) (30)
Risk Factors and Microbial Distribution of Urinary Tract Infections Following Radical Cystectomy. (2016) (30)
Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model (2016) (29)
Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. (2015) (29)
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease (2017) (29)
Surgery for vena caval tumor extension in renal cancer (2009) (28)
Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control. (2015) (28)
Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. (2018) (28)
Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. (2015) (28)
The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. (2015) (27)
Predicting survival of men with recurrent prostate cancer after radical prostatectomy. (2016) (27)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management (2022) (26)
The androgen receptor and stem cell pathways in prostate and bladder cancers (review). (2011) (26)
Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: a contemporary evaluation (2016) (25)
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. (2020) (25)
CT Urography for Diagnosis of Upper Urinary Tract Urothelial Carcinoma: Are Both Nephrographic and Excretory Phases Necessary? (2015) (25)
Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes (2017) (25)
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. (2013) (24)
Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. (2014) (24)
Prognostic significance of lymphatic, vascular and perineural invasion for bladder cancer patients treated by radical cystectomy. (2017) (24)
The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy (2017) (24)
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. (2020) (23)
Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. (2012) (23)
Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. (2019) (22)
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists. (2017) (22)
Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. (2015) (22)
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. (2022) (22)
Development and acceptability testing of a patient decision aid for urinary diversion with radical cystectomy. (2019) (22)
Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. (2009) (22)
Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. (2019) (22)
Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. (2011) (21)
Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification (2017) (21)
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy (2016) (21)
The evolving management of small renal masses (2009) (21)
High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma (2015) (20)
A rare case of painless gross hematuria: primary localized AA-type amyloidosis of the urinary bladder. (2002) (20)
Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. (2017) (20)
Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging? (2017) (20)
The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. (2016) (20)
Intravesical formalin for hemorrhagic cystitis: A contemporary cohort. (2017) (20)
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population (2010) (20)
Percutaneous renal cryoablation after partial nephrectomy: technical feasibility, complications and outcomes. (2013) (20)
Sperm cryopreservation and in vitro fertilization/intracytoplasmic sperm injection in men with congenital bilateral absence of the vas deferens: a success story. (2004) (20)
Abnormal selective cytology results predict recurrence of upper-tract transitional-cell carcinoma treated with ureteroscopic laser ablation. (2004) (20)
Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. (2020) (20)
Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy (2014) (19)
Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. (2021) (19)
The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. (2015) (19)
Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy (2011) (19)
Impact of Radical Prostatectomy on Long‐Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration (2017) (19)
Reduced Lecithin (2004) (19)
Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. (2019) (19)
Perioperative management and oncological outcomes following radical cystectomy for bladder cancer: a matched retrospective cohort study (2016) (19)
SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. (2021) (18)
Late recurrence after radical cystectomy: patterns, risk factors and outcomes. (2014) (18)
Percutaneous Cryoablation of Clinical T2 (> 7 cm) Renal Masses: Technical Considerations, Complications, and Short-Term Outcomes. (2015) (18)
Reduced Lecithin:Retinol Acyltransferase Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer (2004) (18)
The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated meta-Analysis. (2021) (18)
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy (2021) (18)
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. (2007) (18)
Surgical management of high risk prostate cancer: the Mayo Clinic experience. (2008) (18)
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val (2011) (18)
Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease (2012) (17)
Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma (2012) (17)
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. (2019) (17)
Gender-specific survival following radical cystectomy for pT4 bladder cancer (2014) (17)
Percutaneous Clinical T1a Renal Mass Ablation in the Octogenarian and Nonagenarian: Oncologic Outcomes and Morbidity. (2014) (17)
Carcinoma: Clinicopathologic Correlations and Association with Survival (2008) (16)
Urinary collecting system invasion is associated with poor survival in patients with clear‐cell renal cell carcinoma (2017) (16)
The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. (2015) (16)
Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy (2019) (16)
Safety and Efficacy of Percutaneous Image-guided Cryoablation of Completely Endophytic Renal Masses. (2019) (16)
Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. (2019) (16)
Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. (2016) (16)
Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors (2016) (16)
Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort (2017) (16)
The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. (2018) (15)
Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. (2013) (15)
Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications. (2012) (15)
Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. (2017) (15)
More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. (2018) (15)
Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy (2016) (15)
A case of incidental adrenocortical oncocytoma (2006) (15)
Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass (2017) (15)
Intravesical silver nitrate for refractory hemorrhagic cystitis. (2016) (14)
Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma (2016) (14)
Percutaneous Image-Guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. (2019) (14)
Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. (2013) (14)
Temporal trends in venous thromboembolism after radical cystectomy. (2018) (14)
Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi‐Institutional Study (2017) (14)
Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial. (2020) (14)
Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumors: Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, Cadeddu JA, Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX (2008) (14)
Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. (2010) (14)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up (2022) (14)
Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. (2016) (14)
Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma (2018) (13)
PARANEOPLASTIC SARCOID-LIKE REACTIONS AND THE EYE (2015) (13)
Persistent, long-term risk for ureteroenteric anastomotic stricture formation: the case for long term follow-up. (2020) (13)
Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes. (2018) (12)
The utility of sildenafil citrate for infertile men with sexual dysfunction: a pilot study (2007) (12)
Long Term Outcomes of Patients with Low Grade Cystic Renal Epithelial Neoplasms. (2019) (12)
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. (2021) (12)
Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy (2014) (12)
Utilization and Outcomes of Radical Cystectomy for High‐grade Non–muscle‐invasive Bladder Cancer in Elderly Patients (2017) (12)
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. (2019) (12)
The effect of Gleason score on the predictive value of prostate‐specific antigen doubling time (2009) (12)
Patient factors associated with 30-day complications after partial nephrectomy: A contemporary update. (2017) (11)
Percutaneous renal cryoablation in obese and morbidly obese patients. (2013) (11)
Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes (2019) (11)
Retinoid receptor mRNA expression profiles in human bladder cancer specimens. (2005) (11)
Oncologic surveillance in bladder cancer following radical cystectomy: A systematic review and meta-analysis. (2016) (11)
The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology (2018) (11)
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. (2016) (11)
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. (2018) (11)
Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. (2019) (11)
Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. (2009) (11)
Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. (2017) (10)
Imaging following renal ablation: what can we learn from recurrent tumors? (2018) (10)
The Association of Aspirin Use with Survival Following Radical Cystectomy (2018) (10)
Microencapsulation of Leydig cells: A new system for the therapeutic delivery of testosterone (1999) (10)
Tumor thrombus. (2013) (10)
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. (2020) (10)
Choroidal Involvement in Erdheim-Chester Disease. (2015) (10)
Iatrogenic splenectomy during nephrectomy for renal tumors (2013) (10)
Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. (2013) (10)
Abstract 2924: Constitutively active androgen receptor splice variants function independently of full-length androgen receptor in a cell-based model of castrate-resistant prostate cancer (2012) (10)
T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. (2009) (10)
Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. (2021) (9)
Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. (2017) (9)
The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer (2021) (9)
Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. (2019) (9)
Tumor Cell andTumorVasculature Expression of B 7-H 3 Predict Survival in Clear Cell Renal Cell Carcinoma (2008) (9)
Synchronous nephron‐sparing approaches for bilateral renal masses: peri‐operative and renal functional outcomes (2018) (9)
Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. (2015) (9)
Ultrasound-Guided Transhepatic Radiofrequency Ablation of Renal Tumors: A Safe and Effective Approach (2014) (9)
The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer (2021) (9)
A Comparison of Bleeding Complications in Patients Undergoing Percutaneous Renal Cryoablation Using Cryoprobes with and without Heat-Based Track Ablation. (2018) (9)
Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer (2017) (9)
Treatment of the 2 to 3 cm renal mass. (2010) (8)
Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy (2016) (8)
Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. (2017) (8)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions (2022) (8)
Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome (2021) (8)
Partial versus radical nephrectomy in clinical T2 renal masses (2021) (8)
Surgical Management and Oncologic Outcomes of Recurrent Venous Tumor Thrombus after Prior Nephrectomy for Renal Cell Carcinoma. (2016) (7)
Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy (2017) (7)
Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. (2019) (7)
The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy (2013) (7)
Safety and Efficacy of Retrograde Pyeloperfusion for Ureteral Protection during Renal Tumor Cryoablation. (2020) (7)
Treatment Outcomes in Patients with Symptomatic Lymphoceles Following Radical Prostatectomy Depend Upon Size and Presence of Infection. (2020) (7)
Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder. (2020) (7)
Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. (2013) (7)
Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. (2020) (7)
Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. (2021) (7)
Outcomes of patients with sarcomatoid renal cell carcinoma: The Mayo Clinic experience. (2013) (7)
The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. (2021) (7)
Assessment of Isochromosome 12p & 12p Abnormalities in Germ Cell Tumors Using FISH, SNP-Arrays & NGS/ Mate-Pair Sequencing. (2021) (7)
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. (2005) (7)
Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors — a major reason for enhanced chemosensitivity? (2017) (7)
Safety and Efficacy of Extended Duration of Thromboembolic Prophylaxis Following Radical Cystectomy: An Initial Institutional Experience (2016) (7)
Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy (2017) (7)
Expression of Immunosuppresive B 7-H 3 Ligandby Hormone-Treated Prostate Cancer Tumors andMetastases (2009) (7)
Ureteroileal anastomosis with intraluminal visualization: technique and outcomes. (2010) (7)
Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer (2014) (7)
Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer. (2020) (7)
Comprehensive characterization of perioperative reoperation following radical cystectomy. (2019) (7)
Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses. (2020) (7)
Dynamic prediction of metastases after radical prostatectomy for prostate cancer (2011) (6)
Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy (2014) (6)
Oncologic surveillance following radical cystectomy: an individualized risk-based approach (2017) (6)
Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. (2015) (6)
The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. (2019) (6)
Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. (2014) (6)
The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. (2019) (6)
Renal Neoplasia with Papillary Architecture Involving the Pelvicalyceal System. (2020) (6)
Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools (2019) (6)
Emulating Target Clinical Trials of Radical Nephrectomy with or without Lymph Node Dissection for Renal Cell Carcinoma. (2020) (6)
Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience (2019) (6)
PD12-07 A PHASE III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH HIGH-GRADE, BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (2020) (6)
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. (2018) (6)
The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy (2016) (6)
A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. (2021) (6)
Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20 (2018) (6)
Defining radical cystectomy using the ICD-10 procedure coding system. (2021) (5)
Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer (2018) (5)
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? (2015) (5)
Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer (2016) (5)
Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study. (2012) (5)
641: Is Partial Nephrectomy for Small Renal Masses Associated with Improved Overall Survival Compared with Radical Nephrectomy? (2007) (5)
544 Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in pT3N0 prostate cancer patients treated with radical prostatectomy: Results of a multi-institutional analysis (2016) (5)
THERAPEUTIC DELIVERY OF TESTOSTERONE USING MICROENCAPSULATED LEYDIG CELLS (1999) (5)
MP69-12 THE ASSOCIATION OF STATIN THERAPY WITH CLINICOPATHOLOGIC OUTCOMES AND SURVIVAL AMONG PATIENTS WITH LOCALIZED RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY (2015) (5)
A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease (2018) (5)
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high‐risk men (2019) (5)
A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging. (2020) (5)
Comprehensive handbook for developing a bladder cancer cystectomy database. (2013) (5)
Increased Expression of the PolycombGroup Gene , EZH 2 , in Transitional Cell Carcinoma of the Bladder (2005) (5)
1073 RADICAL NEPHRECTOMY FOR BENIGN RENAL MASSES IS ASSOCIATED WITH DIMINISHED OVERALL SURVIVAL COMPARED WITH PARTIAL NEPHRECTOMY (2011) (5)
Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma (2018) (5)
Salvage cryotherapy versus salvage radical prostatectomy for radiorecurrent prostate cancer: Long-term oncologic outcomes (2019) (4)
Percutaneous Cryoablation of Renal Cell Carcinoma with Sinus Vein Involvement Based on Preprocedural Imaging. (2017) (4)
Reply to Samuel Bishara and Jim Adshead's letter to the editor re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45. (2013) (4)
THE SEXUAL DYSFUNCTION OF LOUIS XVI: A CONSEQUENCE OF INTERNATIONAL POLITICS, ANATOMY, OR NAÏVETÉ? (2010) (4)
723: Long Term Outcome after Radical Prostatectomy for Patients with Lymph Node Positive Prostate Cancer in the PSA ERA (2007) (4)
The evolving role of lymphadenectomy for bladder cancer: why, when, and how (2019) (4)
1238 ANATOMICAL FEATURES OF ENHANCING RENAL MASSES PREDICT HISTOLOGY AND GRADE - AN ANALYSIS USING NEPHROMETRY (2010) (4)
Long-term outcomes of incidental prostate cancer at radical cystectomy. (2020) (4)
897 Gender-specific differences in clinicopathologic outcomes following radical cystectomy: An international multi-institutional study of over 8,000 patients (2014) (4)
Squamous Cell Carcinoma of the Bladder is Not Associated with High-Risk HPV. (2020) (4)
Patterns of Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: Unique Identification of Sites of Recurrence Impacting Clinical Management (2016) (4)
Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing (2021) (4)
Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. (2017) (4)
PD17-06 RANDOMIZED PHASE II TRIAL OF INTRAVESICAL ADENOVIRAL MEDIATED INTERFERON-α GENE THERAPY WITH THE EXCIPIENT SYN3 (RAD-IFNα/SYN3) IN PATIENTS WITH BCG REFRACTORY OR RELAPSING HIGH GRADE (HG) NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) (2015) (4)
LONG-TERM SURVIVAL AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH HIGH RISK PROSTATE CANCER IN THE PSA ERA (2008) (4)
Examining the association between adiposity and biochemical recurrence after radical prostatectomy. (2018) (4)
Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results from a Multi-center Study. (2022) (4)
Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse (2018) (4)
A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy. (2021) (3)
573 THE RELATIONSHIP OF LYMPH NODE DISSECTION WITH RECURRENCE AND SURVIVAL FOR PATIENTS TREATED WITH NEPHRECTOMY FOR HIGH-RISK RENAL CELL CARCINOMA (2012) (3)
Collecting duct carcinoma: A single-institution retrospective study. (2021) (3)
Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy (2019) (3)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. (2022) (3)
A painless testicular mass in a 50-year-old man. Leydig cell tumor of the testis, microcystic variant. (2006) (3)
All men are created equal: benign prostatic hyperplasia, surgery, and politics. (2013) (3)
Does ureteral stent drainage prior to cystectomy increase the risk of subsequent upper tract urothelial carcinoma and ureteral complications? (2020) (3)
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial. (2020) (3)
Trends in Extended-Duration Venous Thromboembolism Prophylaxis following Radical Cystectomy. (2019) (3)
Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience (2021) (3)
Patient-Reported Outcomes After Percutaneous Renal Ablation: Initial Experience. (2019) (3)
MP09-16 CONTEMPORARY MAPPING OF POST-PROSTATECTOMY PROSTATE CANCER RELAPSE WITH C-11 CHOLINE PET AND MULTIPARAMETRIC MRI (2016) (3)
Survival for patients with residual tumor at radical cystectomy following chemotherapy: A matched analysis to cystectomy-only patients. (2017) (3)
Efficacy of a Novel Penile Traction Device in Improving Penile Length and Erectile Function Post Prostatectomy: Results from a Single-Center Randomized, Controlled Trial. (2021) (3)
Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. (2019) (3)
1682 COMPARATIVE EFFECTIVENESS OF PARTIAL AND RADICAL NEPHRECTOMY FOR LOCALIZED RENAL TUMORS ON SURVIVAL AND RENAL FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2012) (3)
THE IMPACT OF POSITIVE SURGICAL MARGINS ON MORTALITY FOLLOWING RADICAL PROSTATECTOMY (2009) (3)
Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy. (2022) (3)
1135 DETERMINANTS OF LONG-TERM RENAL FUNCTION FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH URINARY DIVERSION (2011) (3)
MP35-19 THE IMPACT OF EXCESS FAT MASS ON MORTALITY AFTER RADICAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: BEYOND BODY MASS INDEX (2015) (3)
Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer (2021) (3)
Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy (2020) (3)
Commentary on "The association between physical activity and renal cancer: systematic review and meta-analysis." Behrens G, Leitzmann MF, Department of Epidemiology and Preventive Medicine, Regensburg University Medical Center, Regensburg, Germany. Br J Cancer 2013; 108(4):798-811. [Epub 2013 Feb 14 (2014) (3)
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial (2021) (3)
Adult UrologyOncology: Prostate/Testis/Penis/UrethraEditorial Comment (2008) (2)
Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9. (2015) (2)
Bladder Cancer , Version 5 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
Media reporting of ProtecT: a disconnect in information dissemination? (2017) (2)
Defining the Prevalence of Asymptomatic Microscopic Hematuria Among Women With Symptomatic Pelvic Organ Prolapse: Implications for Recommending Subsequent Diagnostic Evaluation. (2017) (2)
Molecular progression of prostate cancer: Androgens and estrogens (2012) (2)
Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases (2020) (2)
Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis (2017) (2)
Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients (2022) (2)
ONCOLOGICAL OUTCOMES COMPARING INTRAVESICAL AND EXTRAVESICAL BLADDER CUFF EXCISION FOLLOWING RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA: PD66‐11 (2017) (2)
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma. (2022) (2)
Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9. (2015) (2)
601: Timing of Androgen Deprivation Therapy and Its Impact on Cancer-Specific Survival after Radical Prostatectomy: A Matched-Cohort Analysis (2007) (2)
Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. (2020) (2)
Factors predicting early mortality after radical cystectomy for urothelial carcinoma in a contemporary cohort of patients. (2020) (2)
1801 COMPLICATIONS AND OUTCOMES FOR PATIENTS WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS: RESULTS FROM THE MAYO CLINIC (2012) (2)
A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. (2019) (2)
RAPID DISEASE PROGRESSION IS THE PRIMARY REASON PATIENTS FAIL TO RECEIVE SYSTEMIC THERAPY FOLLOWING CYTOREDUCTIVE NEPHRECTOMY (CN) (2009) (2)
PD12-02 COST-EFFECTIVENESS OF MAINTENANCE BCG FOR INTERMEDIATE AND HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER (2020) (2)
MP16-02 PHASE III TRIAL OF INTRAVESICAL NADOFARAGENE FIRADENOVEC IN PATIENTS WITH HIGH-GRADE, BCG-UNRESPONSIVE, NON-MUSCLE INVASIVE BLADDER CANCER: TWO YEAR FOLLOW-UP IN THE TA/T1 COHORT (2021) (2)
Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes? (2020) (2)
Access to Urological Care and Internet Connectivity in the United States: A Geospatial Analysis (2019) (2)
Ureteroarterial Fistulas After Robotic and Open Radical Cystectomy (2016) (2)
Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis (2018) (2)
Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. (2022) (2)
PD59-05 COST EFFECTIVENESS OF ADJUVANT PEMBROLIZUMAB AFTER NEPHRECTOMY FOR RCC: INSIGHTS FOR PATIENT SELECTION FROM A MARKOV MODEL (2022) (2)
T CELL COREGULATORY MOLECULE EXPRESSION IN UROTHELIAL CELL CARCINOMA: A POTENTIAL TARGET FOR THERAPY (2008) (2)
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. (2023) (2)
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet? (2011) (2)
The impact of family history on pathological and clinical outcomes in non‐syndromic clear cell renal cell carcinoma (2010) (2)
Outcomes of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who undergo radical cystectomy after BCG and subsequent salvage intravesical therapy. (2020) (2)
MP44-14 PARANEOPLASTIC SYNDROMES ARE ASSOCIATED WITH ADVERSE PROGNOSIS AMONG PATIENTS WITH RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY (2015) (2)
Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: The Fox Chase Cancer Center (FCCC) experience. (2009) (2)
340 LONG-TERM RISK OF CLINICAL PROGRESSION AFTER BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY: THE IMPACT OF TIME TO RECURRENCE (2011) (2)
PD51-08 LUMINAL PRIMARY MUSCLE-INVASIVE BLADDER CANCER PATIENTS ARE LESS LIKELY TO BENEFIT FROM PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY (2021) (2)
Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer (2022) (2)
Advances in robotic prostatectomy (2008) (2)
Primum Non Nocere: Critically Assessing the Morbidity of Prostate Biopsy. (2017) (2)
A prospective randomized EORTC intergroup Phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma (2008) (2)
GEMINI: An open-label, single-arm, phase II trial of intraoperative gemcitabine intravesical instillation in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. (2020) (2)
Percutaneous Cryoablation of the Horseshoe Kidney: An Initial Experience. (2017) (1)
Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes (2017) (1)
Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia (2021) (1)
PD41-10 ROBOTIC RADICAL CYSTECTOMY IS ASSOCIATED WITH SHORTER LENGTH OF STAY AND LESS BLOOD LOSS THAN OPEN RADICAL CYSTECTOMY: RESULTS FROM A LARGE MULTICENTER RETROSPECTIVE COHORT (2018) (1)
MP29-16 INCIDENCE AND RISK FACTORS OF URETEROENTERIC ANASTOMOTIC STRICTURE FOLLOWING RADICAL CYSTECTOMY WITH URINARY DIVERSION (2015) (1)
Complications of the incision and patient positioning (2009) (1)
Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics (2022) (1)
Incidence and risk factors for peritoneal carcinomatosis following open radical cystectomy. (2019) (1)
A novel clinical decision aid to support personalized treatment selection for patients with CT1 renal cortical masses: Results from a multi-institutional competing risks analysis including performance status and comorbidity. (2020) (1)
MP35-02 PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO CAN PREDICT TUMOR AGGRESSIVENESS IN NEWLY DIAGNOSED RENAL LESIONS (2015) (1)
Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data (2022) (1)
PD35-07 EVALUATION AND MANAGEMENT OF RENAL FOSSA RECURRENCE FOLLOWING NEPHRECTOMY FOR RENAL CELL CARCINOMA (2015) (1)
MP31-07 SIMULTANEOUS VERSUS STAGED PARTIAL NEPHRECTOMIES FOR BILATERAL SYNCHRONOUS SOLID RENAL MASSES (2019) (1)
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model (2022) (1)
396 CANCER-SPECIFIC MORTALITY FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER WITH LYMPH NODE INVOLVEMENT: IMPACT OF DISEASE FEATURES AND ADJUVANT CHEMOTHERAPY (2013) (1)
1327 THE PRESENCE OF EXTRAPROSTATIC EXTENSION INCREASES THE RISK OF DEATH FROM PROSTATE CANCER AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH PT3B DISEASE (2012) (1)
Comment on: Radical Nephrectomy for pT1a Renal Masses May be Associated With Decreased Overall Survival Compared With Partial Nephrectomy. Authors' reply (2008) (1)
Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) (2021) (1)
Intraoperative application of platelet-rich plasma to the neurovascular bundles during radical prostatectomy: A prospective clinical trial (2020) (1)
Accommodating heterogeneous missing data patterns for prostate cancer risk prediction (2021) (1)
Evolving Changes in the Delivery of Health Services: A Place for Urological Homecare? (2019) (1)
25: Delay in time to Nephroureterectomy for Patients Undergoing Ureteroscopic Biopsy and Laser Tumor Ablation of Upper Tract Transitional Cell Carcinoma Does not Impact Postoperative Disease Status (2004) (1)
CT findings and diagnostic performance of upper urinary tract carcinoma in situ (2022) (1)
886: Bladder Cancer Incidence and Risk Factors Among Men with Prostate Cancer: Results from Capsuretm (2006) (1)
IDENTIFICATION OF POTENTIAL SERUM MARKERS IN CLEAR CELL RENAL CELL CARCINOMA (2008) (1)
988 OPEN, LAPAROSCOPIC, AND ROBOTIC PARTIAL NEPHRECTOMY: A SINGLE INSTITUTION ANALYSIS WITH PERIOPERATIVE AND ONCOLOGIC OUTCOMES (2010) (1)
ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: A LONG‐TERM SURVIVAL ANALYSIS: PD72‐06 (2017) (1)
Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer (2022) (1)
Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study (2022) (1)
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. (2023) (1)
MP25-06 COMPLETE METASTASECTOMY FOR RENAL CELL CARCINOMA IN THE CONTEMPORARY ERA (2019) (1)
Lymph node dissection is not associated with increased 30-day complications among patients undergoing radical nephrectomy for renal cell carcinoma: A propensity-score based analysis (2017) (1)
Coregulatory Molecule Expression in Urothelial Cell Carcinoma : Clinicopathologic Correlations and Associationwith Survival (2008) (1)
Survival following upfront cytoreductive nephrectomy versus targeted therapy for metastatic renal cell carcinoma. (2018) (1)
The impact of surgical resection on circulating tumor-reactive cytotoxic T cells for patients with renal tumors. (2020) (1)
MP05-13 PROSTATE MRI BEFORE RADICAL PROSTATECTOMY DOES NOT AFFECT MARGINS AND FUNCTIONAL OUTCOMES (2016) (1)
MP16-01 EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH CARCINOMA IN SITU (CIS), BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC): LONGER-TERM FOLLOW-UP FROM THE PHASE III TRIAL (2021) (1)
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy. (2020) (1)
MP46-15 PROSPECTIVE VALIDATION OF THE FOUR KALLIKREIN PANEL IN ACADEMIC CLINICAL PRACTICE (2018) (1)
Frequency and Predictors of Renal Transplantation Among Patients Rendered Surgically Anephric for Sporadic Renal Cancer. (2019) (1)
MP55-16 SARCOPENIC OBESITY IN BLADDER CANCER: ADDITIVE RISKS OF CACHEXIA AND OBESITY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY? (2014) (1)
678 NATURAL HISTORY OF BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY WITH ADJUVANT RADIATION THERAPY (2012) (1)
Development of a technique for evaluating the presence of malignant cells in prostatic fluid during robotic prostatectomy. (2020) (1)
Unplanned Conversion From Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk Factors (2022) (1)
Microhematuria: AUA/SUFU Guideline-American Urological Associ (2020) (1)
LONG TERM OUTCOMES OF PATIENTS WITH CYSTIC CLEAR CELL RENAL CELL CARCINOMA: MP55‐07 (2017) (1)
MP54-19 THE EFFECT OF METFORMIN IN PATIENTS WITH SURGICALLY TREATED RENAL CELL CARCINOMA (2014) (1)
Sperm cryopreservation and IVF/ICSI in men with congenital bilateral absence of the vas deferens: a success story (2003) (1)
Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy (2021) (1)
Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. (2017) (1)
MP50-17 LATE RECURRENCE FOLLOWING RADICAL CYSTECTOMY: PATTERNS, RISK FACTORS, AND OUTCOMES (2014) (1)
Use of comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys to investigate the role of nonmodifiable factors in determining ultimate renal function. (2011) (1)
1423: The Impact of Gleason Score on the Predictive Value of PSA Doubling Time (2007) (1)
SURGICAL RESECTION OF ISOLATED RETROPERITONEAL LYMPH NODE RECURRENCE OF RENAL CELL CARCINOMA (2008) (1)
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and Nephroureterectomy. (2022) (1)
The association of anxiety and depression with mortality risk among patients with clear cell renal cell carcinoma undergoing nephrectomy. (2019) (1)
A Diagnostic Approach to Paratesticular Lesions with Tubulopapillary Architecture: A Series of 16 Serous Borderline Tumors/Low-Grade Serous Carcinoma & 14 Well-Differentiated Papillary Mesothelial Tumors and Mesothelioma. (2022) (1)
PD34-02 SALVAGE RADICAL PROSTATECTOMY VERSUS SALVAGE CRYOTHERAPY FOR LOCALIZED RADIORECURRENT PROSTATE CANCER: COMPARATIVE LONG-TERM OUTCOMES (2018) (1)
Survivorship and quality of life in prostate cancer (2015) (1)
When Less Is More: The Comparative Effectiveness of Partial Versus Radical Nephrectomy. (2021) (1)
MP29-15 CLINICAL OUTCOMES OF URETEROILEAL ANASTOMOTIC STRICTURE MANAGEMENT (2015) (1)
Increased Utilization of External Beam Radiation Therapy Relative to Cystectomy for Localized, Muscle-Invasive Bladder Cancer: A SEER Analysis (2017) (1)
Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high‐risk prostate cancer (2013) (1)
Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub (2014) (1)
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. (2019) (1)
MP59-20 SURGICAL RESECTION OF ISOLATED RETROPERITONEAL LYMPH NODE RECURRENCE OF RCC: RESULTS FROM A MULTI-INSTITUTIONAL INTERNATIONAL COHORT (2015) (1)
547 A NATIONAL SURVEY OF RADIATION ONCOLOGISTS AND UROLOGISTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER (2013) (1)
Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. (2022) (1)
Infections/Inflammation of the Genitourinary Tract: Kidney & Bladder IIMP20-20 CYSTECTOMY FOR REFRACTORY HEMORRHAGIC CYSTITIS: CONTEMPORARY ETIOLOGY, PRESENTATION AND OUTCOMES (2015) (1)
Victor Fray Marshall: twentieth century renaissance urologist. (2006) (1)
Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) (2021) (1)
METASTASECTOMY FOR PATIENTS WITH MULTIPLE METASTASES OF RENAL CELL CARCINOMA: A COMPARISON OF COMPLETE VERSE INCOMPLETE RESECTION (2009) (1)
PD04-01 RENAL CELL CARCINOMA WITH ISOLATED LYMPH NODE INVOLVEMENT: NATURAL HISTORY AND PREDICTORS OF ONCOLOGIC OUTCOMES (2016) (1)
670 HIGH RATES OF ADVANCED DISEASE, COMPLICATIONS, AND DECLINE OF RENAL FUNCTION AFTER RADICAL NEPHROURETERECTOMY: FURTHER EVIDENCE TO SUPPORT THE INCREASED USE OF NEOADJUVANT CHEMOTHERAPY? (2011) (1)
MP56-14 PREDICTORS AND ONCOLOGIC OUTCOMES OF PT0 PROSTATE CANCER IN RADICAL PROSTATECTOMY SPECIMENS (2015) (1)
Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9. (2015) (1)
PD51-03 IMPACT OF NEOADJUVANT CHEMOTHERAPY ON PATHOLOGIC DOWNSTAGING IN PATIENTS WITH VARIANT HISTOLOGY UNDERGOING RADICAL CYSTECTOMY (2021) (0)
Oncologic outcomes in patients with residual invasive upper tract urothelial carcinoma following neoadjuvant chemotherapy. (2023) (0)
957 The impact of non-clear cell histology on outcome for patients with renal cell carcinoma and venous tumor thrombus (2013) (0)
CHARACTERIZATION OF ONCOLYTIC MEASLES VIRUS IN PATIENT‐DERIVED RENAL CELL CARCINOMA XENOGRAFTS GROWN ON CHICKEN CHORIOALLANTOIC MEMBRANES AS A MODEL FOR EARLY METASTATIC DISEASE: MP72‐15 (2018) (0)
MP06-02 SAFETY AND EFFICACY OF EXTENDED-DURATION THROMBOEMBOLIC PROPHYLAXIS FOLLOWING RADICAL CYSTECTOMY (2016) (0)
MP57-10 RISK FACTORS FOR MAJOR COMPLICATIONS AND PERIOPERATIVE MORTALITY FOLLOWING SURGICAL RESECTION OF RENAL CELL CARCINOMA WITH UPPER LEVEL IVC THROMBUS: A CONTEMPORARY MULTI-CENTER EXPERIENCE (2014) (0)
PD27-07 AUTOMATED OPERATIVE REPORTS FOR ROBOTIC RADICAL PROSTATECTOMY USING AN ARTIFICIAL INTELLIGENCE PLATFORM (2023) (0)
IMPACT OF TIME FROM BIOPSY TO SURGERY ON COMPLICATIONS, FUNCTIONAL AND ONCOLOGIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY: MP77‐17 (2017) (0)
MP32-18 SURVIVAL OUTCOMES AND SALVAGE TREATMENTS FOR LOCAL BLADDER CANCER RECURRENCES AFTER RADICAL CYSTECTOMY (2019) (0)
MP01-17 ASSOCIATION OF DISTANCE TO TREATMENT FACILITY WITH SURVIVAL AND QUALITY OUTCOMES FOLLOWING RADICAL CYSTECTOMY: A MULTI-INSTITUTIONAL STUDY (2016) (0)
MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3N0 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS (2016) (0)
1413 PATIENTS WITH MICROPAPILLARY BLADDER CANCER HAVE COMPARABLE STAGE-ADJUSTED SURVIVAL TO PATIENTS WITH UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY: A MATCHED COHORT ANALYSIS (2012) (0)
Prospective validation of microseminoprotein‐β added to the 4Kscore in predicting high‐grade prostate cancer in an international multicentre cohort (2020) (0)
1756 SIGNET RING VERSUS UROTHELIAL CARCINOMA OF THE BLADDER IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A MATCHED COHORT ANALYSIS (2013) (0)
Intraoperative application of platelet-rich plasma to the neurovascular bundles during radical prostatectomy: A prospective clinical trial. (2020) (0)
Reply by Authors. (2019) (0)
THE IMPACT OF ADJUVANT THERAPY AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH PATHOLOGICAL T3b PROSTATE CANCER (2008) (0)
Reply by the authors (2010) (0)
347 EVALUATING COMPETING RISKS OF DEATH IN PATIENTS WITH LOCALIZED PROSTATE CANCER USING A COMPREHENSIVE NOMOGRAM: A NOVEL PROGNOSTIC MODEL FROM THE CAPSURE DATABASE (2011) (0)
PD28-10 ASSESSING THE IMPACT OF HOSPITAL DISMISSAL SUMMARY READABILITY ON PATIENT OUTCOMES FOLLOWING PROSTATECTOMY (2021) (0)
958: The Lusk Kidney: Medical Student Hoax or Evidence of the Whitechapel Murders? (2006) (0)
Effect of routine ipsilateral adrenalectomy on cancer-specific survival and risk of adrenal insufficiency for patients with pT3/4 renal cell carcinoma. (2011) (0)
1897 OUTCOMES AND CLINICOPATHOLOGIC PREDICTORS ASSOCIATED WITH LATE RECURRENCE AFTER RADICAL CYSTECTOMY (2012) (0)
2014 ULTRASOUND-GUIDED IMPLANTATION OF ELECTROMAGNETIC TRANSPONDERS INTO THE PROSTATE BED FOR LOCALIZATION AND TRACKING DURING INTENSITY MODULATED RADIATION THERAPY FOLLOWING RADICAL PROSTATECTOMY (2010) (0)
Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing? (2021) (0)
75 Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients (2013) (0)
MP72-12 ARTIFICIAL INTELLIGENCE ANALYSIS OF PRE-OPERATIVE ECGS CAN PREDICT POST-OPERATIVE DEATH AND MAJOR CARDIAC COMPLICATIONS (2023) (0)
Does the diagnostic modality for upper tract urothelial carcinoma prior to radical nephroureterectomy influence the risk of subsequent intravesical recurrence? (2021) (0)
What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series (2019) (0)
Effect of Surgical Care Team Consistency During Urologic Procedures on Surgical Efficiency and Perioperative Outcomes. (2023) (0)
Factors associated with poor survival outcomes in patients with prostate cancer (PCa) with radiographic disease progression in the setting of low PSA. (2023) (0)
MP24-07 TIME TRENDS IN THE USE OF SECONDARY TREATMENTS FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2015) (0)
When should salvage radiation therapy be associated with concomitant hormonal therapy in patients affected by prostate cancer? The key role of PSA doubling time (2018) (0)
MP64-19 FACTORS PREDICTING BLOOD LOSS AND POSITIVE MARGINS AT TIME OF PARTIAL NEPHRECTOMY: ANALYSIS OF A CONTEMPORARY COHORT (2016) (0)
PD12-04 MALIGNANT URETEROINTESTINAL ANASTOMOTIC STRICTURE FOLLOWING RADICAL CYSTECTOMY: PATTERNS, RISK FACTORS, AND OUTCOMES (2016) (0)
Association of prior pelvic radiation with long-term oncologic outcomes following radical cystectomy. (2017) (0)
MP70-15 INCREASING COMPLEXITY OF TUMOR THROMBI IN RENAL CELL CARCINOMA OVER 40 YEARS OF EXPERIENCE (2015) (0)
515 OBJECTIFYING SURGICAL DECISION-MAKING FOR THE ENHANCING RENAL MASS (2010) (0)
RENAL FUNCTIONAL OUTCOMES IN PATIENTS UNDERGOING PARTIAL NEPHRECTOMY OR PERCUTANEOUS CRYOABLATION FOR A SOLITARY RENAL MASS: MP59‐14 (2017) (0)
PD34-02 THE KEY ROLE OF PSA DOUBLING TIME IN PATIENTS TREATED WITH SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY: IMPLICATIONS FOR THE EXTENT OF RADIATION AND THE CONCOMITANT USE OF HORMONAL THERAPY (2021) (0)
Survival outcomes according to salvage treatments for local bladder cancer recurrences following radical cystectomy (2019) (0)
940 ADJUVANT HORMONAL THERAPY DOES NOT ADVERSELY IMPACT OVERALL SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR MEN WITH HIGH RISK PROSTATE CANCER WHEN STRATIFIED BY CHARLSON COMORBIDITY INDEX OR CARDIOVASCULAR RISK FACTORS (2012) (0)
PD35-11 PREOPERATIVE MULTIVARIABLE PROGNOSTIC MODELS FOR PREDICTION OF SURVIVAL AND MAJOR COMPLICATIONS FOLLOWING SURGICAL RESECTION OF RENAL CELL CARCINOMA WITH SUPRAHEPATIC CAVAL TUMOR THROMBUS (2015) (0)
Editorial comment. (2010) (0)
MP06-02 EVALUATING THE IMPACT OF SURGICAL CARE TEAM CONSISTENCY DURING UROLOGIC SURGERY ON OPERATING ROOM EFFICIENCY AND PERIOPERATIVE OUTCOMES (2023) (0)
724 Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma (2015) (0)
1614 COMPARATIVE PERFORMANCE OF COMORBIDITY INDICES FOR ESTIMATING PERIOPERATIVE AND 5-YEAR ALL-CAUSE MORTALITY FOLLOWING RADICAL CYSTECTOMY (2013) (0)
MP78-02 URINARY COLLECTING SYSTEM INVASION IS ASSOCIATED WITH POOR SURVIVAL IN CLEAR CELL RENAL CELL CARCINOMA PATIENTS (2016) (0)
MP41-13 THE ASSOCIATION OF CHRONIC KIDNEY DISEASE WITH TUMOR RECURRENCE AND MORTALITY FOLLOWING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA (2018) (0)
1108: Surgical Management, Complications, and Outcome of Vascular Bypass for Renal Cell Carcinoma with Venous Tumor Thrombus (2007) (0)
MP-19.15: Urinary fluorescence in situ hybridization predicts long-term disease status after bacillus Calmette-Guerin therapy (2007) (0)
Survival outcomes for patients with surgically induced end-stage renal disease. (2019) (0)
3: The Impact of Demographics on Patient Age at the Time of Referral for Evaluation of Undescended Testes in the Pediatric Population (2005) (0)
Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma (2006) (0)
1903 PATHOLOGIC SUBSTAGING IMPROVES PROGNOSTIC STRATIFICATION IN PATIENTS WITH PT3 BUT NOT PT2 UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY (2012) (0)
EAU and NCCN surveillance guidelines for bladder cancer: Do they effectively capture recurrences following cystectomy? (2014) (0)
Surveillance and Monitoring (2015) (0)
Plan to Attend! 2016 Mayo Clinic Reviews in Urology (2016) (0)
1359 RENAL MASSES UNDER ACTIVE SURVEILLANCE ARE MORE OFTEN RADIOGRAPHICALLY “SIMPLE” THAN THOSE UNDERGOING IMMEDIATE INTERVENTION (2010) (0)
Prognostic impact of different Gleason patterns within grade group 4 prostate cancer in radical prostatectomy specimens (2021) (0)
MP5-03 IS AN EGFR < 60 ML/MIN/1.73M2 A CONTRAINDICATION TO CONTINENT URINARY DIVERSION? (2014) (0)
PO-0870: Fitting data of relapse-free survival after postprostatectomy RT with a comprehensive TCP model (2016) (0)
PD46-12 LONG TERM OUTCOMES OF PATIENTS WITH LOW GRADE CYSTIC EPITHELIAL RENAL NEOPLASMS (2019) (0)
Surgical and oncologic outcomes of surgery in early metastatic seminoma: Multi-institutional retrospective study (2023) (0)
The prognostic significance of persistently elevated PSA after radical prostatectomy is highly associated with pathological stage: Implications for timely use of salvage treatments (2018) (0)
208: An Expanded Look-Up Table for Predicting Prostate Biopsy Outcome Using Readily Available Clinical Variables (2005) (0)
Is there value to routine oncologic surveillance after radical cystectomy? Comparative outcomes of symptomatic versus asymptomatic recurrence. (2021) (0)
Urological Oncology : Bladder , Penis and Urethral Cancer , and Basic Principles of Oncology Re : Factors Influencing the Length of Stay after Radical Cystectomy : Implications for Cancer Care and Perioperative Management (2016) (0)
Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy (2021) (0)
MP38-19 ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY: PROPENSITY-SCORE MATCHED EVALUATION OF SURVIVAL OUTCOMES (2019) (0)
MP65-16 AI DRIVEN ASSESSMENT OF BODY COMPOSITION PARAMETERS IN RADICAL CYSTECTOMY PATIENTS: PREDICTORS OF 90-DAY COMPLICATIONS (2023) (0)
Association of age with utilization of radical cystectomy for high-grade nonmuscle invasive bladder cancer: Results from the National Cancer Database. (2017) (0)
Editorial comment. (2011) (0)
Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy. (2015) (0)
1495 DOES PREOPERATIVE MRI IMPROVE ONCOLOGIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER (2013) (0)
PD02-07 A NOVEL CLINICAL DECISION AID TO SUPPORT PERSONALIZED TREATMENT SELECTION FOR PATIENTS WITH RENAL CORTICAL MASSES ≤7 CM: RESULTS FROM A MULTI-INSTITUTIONAL COMPETING RISKS ANALYSIS INCLUDING PERFORMANCE STATUS AND COMORBIDITY (2020) (0)
Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study (2019) (0)
MP47-03 MAYO CLINIC VALIDATION OF THE AMERICAN UROLOGIC ASSOCIATION RISK GROUPS FOR LOCALIZED RENAL CANCER (2022) (0)
MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS (2016) (0)
1150: Impact of the PSA Era on Pathological and Clinical Outcomes after Radical Prostatectomy in Gleason 8-10 Cancers (2007) (0)
PD08-04 VIRTUAL RENAL MASS BIOPSY: PREDICTING RENAL TUMOR HISTOLOGY ON ABDOMINAL CT IMAGES USING MACHINE LEARNING (2023) (0)
PD24-03 SURVIVAL FOLLOWING UPFRONT CYTOREDUCTIVE NEPHRECTOMY VERSUS TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA (2018) (0)
422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma (2021) (0)
Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis (2022) (0)
RADICAL CYSTECTOMY AFTER PRIOR PARTIAL CYSTECTOMY FOR UROTHELIAL CARCINOMA: PERIOPERATIVE AND ONCOLOGIC OUTCOMES: MP21‐06 (2017) (0)
65 SURGICAL VOLUME PREDICTS THE LIKELIHOOD OF OFFERING ELECTIVE PARTIAL NEPHRECTOMY AMONG KIDNEY SURGEONS IN THE AMERICAN UROLOGIC ASSOCIATION (2011) (0)
MP22-01 WHAT IS THE BEST DEFINITION OF BIOCHEMICAL RESPONSE TO SALVAGE RADIATION THERAPY IN PROSTATE CANCER PATIENTS TREATED FOR PSA RISING AFTER RADICAL PROSTATECTOMY? RESULTS FROM A MULTI-INSTITUTIONAL SERIES (2019) (0)
PARTIAL NEPHRECTOMY VERSUS CRYOABLATION FOR TUMORS IN SOLITARY KIDNEYS: A PROPENSITY SCORE ANALYSIS: MP100‐17 (2017) (0)
MP28-12 THE IMPACT OF METASTASIS HISTOPATHOLOGY ON SURVIVAL FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (2023) (0)
MP58-09 THE PATHOLOGIC FEATURES IN RADICAL CYSTECTOMY SPECIMENS OF PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY FOR BLADDER CANCER: IS TUMOR REGRESSION IMPORTANT? (2015) (0)
MP22-20 THE IMPACT OF ADJUVANT RADIATION THERAPY AFTER RADICAL PROSTATECTOMY ON LONG-TERM OUTCOMES (2018) (0)
Perioperative outcomes following surgical resection of renal cell carcinoma with upper level IVC thrombus: A contemporary multicenter experience. (2014) (0)
Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis (2017) (0)
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida. (2022) (0)
608: Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder (2006) (0)
MP58-15 PREDICTING SURVIVAL AFTER RADICAL CYSTECTOMY: VALIDATION OF THE SPARC SCORE (2015) (0)
MP22-20 ASSESSING THE IMPACT AND PREDICTORS OF OTHER-CAUSE MORTALITY IN PATIENTS TREATED WITH POST-PROSTATECTOMY SALVAGE RADIATION THERAPY IN ORDER TO AVOID POSSIBLE OVERTREATMENT: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL STUDY (2019) (0)
Individual patient data meta-analysis of discrimination of the four kallikrein panel associated with the inclusion of prostate volume. (2021) (0)
Presence and Significance of Micrometastases (2009) (0)
CRYOABLATION OF CT1 RENAL MASSES IN “HEALTHIER” PATIENTS: EARLY OUTCOMES FROM MAYO CLINIC: MP100‐06 (2017) (0)
PD11-01 LONG TERM ONCOLOGIC OUTCOMES OF SURGICALLY TREATED RENAL ONCOCYTOMA (2020) (0)
Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma (2022) (0)
PD29-04 NATIONAL UTILIZATION OF RETROPERITONEAL LYMPH NODE DISSECTION AMONG PATIENTS WITH KIDNEY CANCER AND CLINICAL LYMPHADENOPATHY UNDERGOING NEPHRECTOMY (2016) (0)
Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study (2021) (0)
Incidence and predictors of occult preoperative deep vein thrombosis at radical cystectomy for urothelial carcinoma. (2021) (0)
MP64-01 RETROPERITONEAL LYMPH NODE DISSECTION IS NOT ASSOCIATED WITH SURVIVAL OUTCOMES AMONG PATIENTS UNDERGOING RADICAL NEPHRECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: A PROPENSITY-SCORE BASED ANALYSIS (2016) (0)
886 LONG-TERM SURVIVAL AFTER SURGERY VERSUS EXTERNAL BEAM RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER (2011) (0)
Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer (2016) (0)
MP66-12 BIM EXPRESSION IN PERITUMORAL LYMPHOCYTES IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (2018) (0)
There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy (2019) (0)
Orthotopic urinary diversion in the female patient (2008) (0)
PD16-03 THE IMPACT OF PERIOPERATIVE BLOOD TRANSFUSION ON SURVIVAL FOLLOWING NEPHRECTOMY FOR NON METASTATIC RENAL CELL CARCINOMA (2014) (0)
Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies (2023) (0)
The impact of rhabdoid differentiation on prognosis in patients with grade 4 renal cell carcinoma. (2015) (0)
Clinicopathologic characterization and outcomes for patients with renal medullary carcinoma: Results from the National Cancer Database. (2017) (0)
Adjuvant chemotherapy following radical cystectomy: Propensity-score matched evaluation of survival outcomes (2019) (0)
PD13-04 NATURAL HISTORY OF A NON-DIAGNOSTIC UPPER TRACT EVALUATION (2016) (0)
PD59-08 INTERNATIONAL MULTI-INSTITUTIONAL CHARACTERIZATION OF THE PERIOPERATIVE MORBIDITY OF METASTASECTOMY FOR RENAL CELL CARCINOMA (2022) (0)
1588 DIAGNOSIS TO CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER HOW LONG IS SAFE? (2012) (0)
1122 THE SEXUAL DYSFUNCTION OF LOUIS XVI: A CONSEQUENCE OF ANATOMY, INTERNATIONAL POLITICS, OR NAÏVETÉ? (2010) (0)
PD29-06 ONCOLOGIC SURVEILLANCE FOLLOWING SURGICAL RESECTION FOR RENAL CELL CARCINOMA: A NOVEL RISK-BASED APPROACH (2015) (0)
MP48-14 RADICAL VERSUS PARTIAL NEPHRECTOMY FOR CT1 RENAL CELL CARCINOMA: A PROPENSITY-SCORE BASED ANALYSIS (2018) (0)
PD51-01 CONTEMPORARY SURGICAL OUTCOMES OF RETROPERITONEAL LYMPH NODE DISSECTION FROM THE SEMS TRIAL (2022) (0)
CANCER SURVEILLANCE AFTER RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA: A NOVEL RISK‐ADAPTED STRATEGY: MP04‐13 (2017) (0)
Association of intraoperative hypothermia with oncologic outcomes following radical cystectomy. (2020) (0)
MP29-20 FACTORS ASSOCIATED WITH POOR SURVIVAL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS WITH RADIOGRAPHIC DISEASE PROGRESSION IN THE SETTING OF LOW PSA (2023) (0)
Words of wisdom. Re: Overall survival advantage with partial nephrectomy: a bias of observational data? (2015) (0)
Re: Overall Survival Advantage with Partial Nephrect- omy: A Bias of Observational Data? Shuch B, Hanley J, Lai J, et al; Urologic Diseases in America Project (2015) (0)
MP09-11 CONTEMPORARY INCIDENCE AND PREDICTORS OF DOWNGRADING FOR GLEASON 8 PROSTATE CANCER: IMPLICATIONS FOR RISK CLASSIFICATION AND TREATMENT (2019) (0)
Bladder , Penis and Urethral Cancer , and Basic Principles of Oncology Re : Outcome of Patients with Micropapillary Urothelial Carcinoma following Radical Cystectomy : ERBB 2 ( HER 2 ) Amplification Identifies Patients with Poor Outcome (2015) (0)
519 SPARC (SURVIVAL PREDICTION AFTER RADICAL CYSTECTOMY): A MULTIFACTORIAL OUTCOME PREDICTION MODEL FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2013) (0)
MP61-14 THE IMPACT OF NEOADJUVANT CHEMOTHERAPY ON THE TIMING AND SITE OF RECURRENCE FOLLOWING RADICAL CYSTECTOMY (2016) (0)
Survival outcomes and salvage treatments for distant bladder cancer recurrence following radical cystectomy (2018) (0)
Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy (2022) (0)
TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG‐TERM SURVIVAL ANALYSIS: PD72‐03 (2017) (0)
1803 PROGNOSIS IN PATIENTS WITH MULTIPLE METASTATIC LESIONS OF RENAL CELL CARCINOMA (2010) (0)
1002: The Impact of Time from Biopsy to Surgery on Biochemical Recurrence Following Radical Prostatectomy for Clinically Localized Prostate Cancer (2005) (0)
PD49-12 PARTIAL VERSUS RADICAL NEPHRECTOMY IN CLINICAL T2 RENAL MASSES (2020) (0)
The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy (2021) (0)
MP50-10 INCIDENCE AND RISK FACTORS FOR PERIOPERATIVE THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RENAL CELL CARCINOMA AND INFERIOR VENA CAVA TUMOR THROMBUS (2015) (0)
MP42-11 THE IMPACT OF PSYCHIATRIC DIAGNOSES ON PERIOPERATIVE OUTCOMES FOLLOWING RADICAL CYSTECTOMY IN THE STATE OF FLORIDA (2022) (0)
765 COMPARATIVE IMPACT OF SEMINAL VESICAL INVASION VERSUS LYMPH NODE METASTASES ON SURVIVAL FOR PATIENTS FOLLOWING RADICAL PROSTATECTOMY (2013) (0)
MP09-05 DOES THE NEW PROSTATE CANCER GRADING SYSTEM IMPROVE PREDICTION OF CLINICAL RECURRENCE? (2016) (0)
MORE EXTENSIVE LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER SALVAGE RADIOTHERAPY FOR RISING PSA AFTER SURGERY: A LONG‐TERM, MULTI‐INSTITUTIONAL ANALYSIS: PD15‐11 (2017) (0)
PD12-08 THE ASSOCIATION OF LYMPH NODE DISSECTION WITH SURVIVAL IN HIGH-RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE NATIONAL CANCER DATABASE (2018) (0)
Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study (2018) (0)
PD52-06 CLINICAL PREDICTORS AND SURVIVAL OUTCOME OF PATIENT RECEIVING SUBOPTIMAL NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-CENTER EXPERIENCE (2019) (0)
Association of perioperative venous thromboembolism with long-term oncologic outcomes following radical cystectomy. (2017) (0)
PD51-03 PERCUTANEOUS ABLATION OFFERS COMPARABLE ONCOLOGIC CONTROL COMPARED WITH PARTIAL NEPHRECTOMY FOR cT1 RENAL MASSES (2019) (0)
The Association Between Mood and Anxiety Disorders with Perioperative Outcomes Following Radical Cystectomy. (2022) (0)
MP64-01 PATIENT REPORTED QUALITY OF LIFE MEASURES 15 YEARS POST-RADICAL PROSTATECTOMY: A MATCHED COMPARISON OF OPEN RETROPUBIC AND ROBOT ASSISTED TECHNIQUES (2020) (0)
MP30-03 POSITIVE PREDICTIVE VALUE OF MPMRI IN MEN UNDER ACTIVE SURVEILLANCE: CAN THE BIOPSY HISTORY INFLUENCE RADIOLOGICAL ASSESSMENT? (2021) (0)
MP61-20 ASSOCIATION OF INTRAOPERATIVE HYPOTHERMIA WITH ONCOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2020) (0)
Urethral recurrence following radical cystectomy: Risk factors and outcomes. (2021) (0)
MP05-09 TRENDS IN EXTENDED-DURATION POSTOPERATIVE VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING RADICAL CYSTECTOMY AMONG COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES (2019) (0)
MP42-14 UPSTAGING OF CHRONIC KIDNEY DISEASE AFTER PARTIAL AND RADICAL NEPHRECTOMY (2021) (0)
PD11-06 COMPREHENSIVE CHARACTERIZATION OF RETURNS TO THE OPERATING ROOM FOLLOWING RADICAL CYSTECTOMY (2018) (0)
The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply. (2021) (0)
Prostate Cancer Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy (2016) (0)
PD49-12 CLINICOPATHOLOGIC CHARACTERISTICS AND SURVIVAL FOR ADULT RENAL SARCOMA: A POPULATION-BASED STUDY (2015) (0)
NATURAL HISTORY OF PATIENTS TREATED WITH SALVAGE RADIATION THERAPY FOR RISING PSA AFTER RADICAL PROSTATECTOMY: A LONG‐TERM SURVIVAL ANALYSIS: PD72‐05 (2017) (0)
951 PROGNOSTIC VALUE OF PATHOLOGIC GLEASON SCORE AFTER NEOADJUVANT HORMONAL THERAPY FOR PREDICTING SYSTEMIC PROGRESSION FOLLOWING RADICAL PROSTATECTOMY (2012) (0)
1846: Critical Analysis of Right-Sided Laparoscopic Live Donor Nephrectomy (2004) (0)
MP42-15 CUTANEOUS URETEROSTOMY FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER: A CONTEMPORARY SERIES (2023) (0)
Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis (2017) (0)
1763: Stage Migration of upper Tract Transitional Cell Carcinoma: An Argument for the Continued Role of Endourologic Diagnosis and Treatment (2004) (0)
628: Molecular Evidence for Hormonal Regulation of Bladder Cancer (2006) (0)
Platinum Priority – Prostate Cancer (2011) (0)
DEFINING THE PREVALENCE OF ASYMPTOMATIC MICROSCOPIC HEMATURIA AMONG WOMEN WITH PELVIC ORGAN PROLAPSE: IMPLICATIONS FOR RECOMMENDING SUBSEQUENT DIAGNOSTIC EVALUATION: PD02‐05 (2017) (0)
PD25-10 ESTIMATION OF THE RISK OF MISSING ADVERSE PATHOLOGICAL PROSTATE CANCER FEATURES AFTER SALVAGE RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR FOCAL SALVAGE THERAPIES (2019) (0)
PD38-06 RISK SCORE PREDICTION MODEL FOR BLADDER CANCER USING COMBINATION OF IMMUNOSCORE AND PATHOLOGICAL STAGING (2016) (0)
MP82-20 URETERAL STENT PLACEMENT VS NEPHROSTOMY TUBE PLACEMENT PRIOR TO RADICAL CYSTECTOMY DOES NOT INCREASE POST-CYSTECTOMY UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
MP64-11 EVALUATION OF SURGICAL COMPLICATIONS IN A CONTEMPORARY SERIES OF PARTIAL NEPHRECTOMY PATIENTS (2016) (0)
475: Abnormal Urinary Cytology Predicts Increased Tumor Recurrence in Upper Tract Transitional Cell Carcinoma Treated with Endoscopic Laser Ablation (2004) (0)
MP01-03 PREVALENCE OF PREOPERATIVE DEEP VEIN THROMBOSIS AND PREDICTIVE VALUE OF D-DIMER ASSAY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA (2016) (0)
LONG‐TERM ONCOLOGIC OUTCOMES OF ADDING RADICAL PROSTATECTOMY TO CASTRATION FOR PATHOLOGICAL NODE‐POSITIVE PROSTATE CANCER: MP53‐16 (2017) (0)
National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy (2017) (0)
MP70-11 RADIOGRAPHIC PREDICTORS OF THE NEED FOR INFERIOR VENA CAVAL RESECTION DURING NEPHRECTOMY FOR PATIENTS WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS (2015) (0)
MP13-07 NEXT-GENERATION LIQUID BIOPSIES USING EXTRACELLULAR VESICLE DETECTION BY NANOSCALE FLOW CYTOMETRY (2019) (0)
MP35-18 SARCOPENIA IS INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY FOLLOWING RADICAL NEPHRECTOMY FOR LOCALIZED RENAL CELL CARCINOMA (2015) (0)
993 PROSTATE TUMOR VOLUME IS INDEPENDENTLY ASSOCIATED WITH CANCER-SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY AND ENHANCES PATIENT RISK STRATIFICATION (2013) (0)
Molecular and Immunophenotypic Correlates of Metastatic Epithelioid Angiomyolipoma Include Alterations of TP53, RB1, and ATRX. (2022) (0)
MP26-07 ARTIFICIAL INTELLIGENCE-ENABLED AUTOMATED IDENTIFICATION OF KEY STEPS IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMY (2023) (0)
430 MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF PREOPERATIVE HYDRONEPHROSIS FOR ADVANCED STAGE UPPER-TRACT UROTHELIAL CARCINOMA (2010) (0)
Incidence, timing, and risk factors for infection after radical cystectomy: Results from the National Surgical Quality Improvement Program. (2016) (0)
PD15-05 WHAT IS THE RISK OF LATE RECURRENCE AND MORTALITY AFTER SALVAGE RADIATION THERAPY FOR POST-PROSTATECTOMY PSA RISING? A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS (2019) (0)
1984 ONCOLOGIC FOLLOW-UP AFTER RADICAL CYSTECTOMY TO DETECT ASYMPTOMATIC RECURRENCE IS ASSOCIATED WITH IMPROVED PATIENT SURVIVAL (2011) (0)
VALIDATION OF THE AMERICAN JOIN COMMITTEE ON CANCER (AJCC) 8TH EDITION PROSTATE CANCER STAGING SYSTEM: MP20‐01 (2017) (0)
MP60-02 PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IS AN INDEPENDENT PREDICTOR OF ADVANCED PATHOLOGIC STAGE AND CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH UROTHELIAL CARCINOMA UNDERGOING RADICAL CYSTECTOMY (2014) (0)
MP32-15 CIGARETTE SMOKING IS ASSOCIATED WITH ADVERSE PATHOLOGIC RESPONSE AND INCREASED DISEASE RECURRENCE AMONG PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY (2019) (0)
MP69-05 EVALUATION OF POST-OPERATIVE COMPLICATIONS AND PROLONGED LENGTH OF STAY FOLLOWING CYTOREDUCTIVE NEPHRECTOMY (2015) (0)
Mass Spectrometry-Based Assessment of Prostate Cancer-Associated Crystalloids Reveals Enrichment for Growth & Differentiation Factor 15 (GDF15). (2023) (0)
RADICAL NEPHRECTOMY WITH OR WITHOUT LYMPH NODE DISSECTION FOR NON‐METASTATIC RENAL CELL CARCINOMA: A MULTI‐INSTITUTIONAL ANALYSIS: MP55‐16 (2017) (0)
MP79-20 STANDARDIZING THE DEFINITION FOR BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY: WHAT PSA CUT-POINT BEST REFLECTS A DURABLE RISE AND PREDICTS SYSTEMIC PROGRESSION? (2014) (0)
PD10-11 AUA AND NCCN SURVEILLANCE GUIDELINES FOR RCC: DO THEY EFFECTIVELY CAPTURE RECURRENCES FOLLOWING NEPHRECTOMY? (2014) (0)
RF33 | PSUN02 Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results from a Multi-center Study (2022) (0)
MP72-13 AI CHARACTERIZATION OF LONGITUDINAL CHANGES IN BODY COMPOSITION: PREDICTORS OF CHANGE AFTER RADICAL CYSTECTOMY (2023) (0)
MP73-11 A COMPREHENSIVE COMPETING RISK CALCULATOR FOR PATIENTS WITH CORTICAL RENAL MASSES < 10CM: A NOVEL CLINICAL DECISION AID FOR SHARED DECISION-MAKING REGARDING INDIVIDUALIZED TREATMENT SELECTION (2016) (0)
PD43-08 THE EFFECT OF PRIOR TURP ON COMPLICATIONS AND LONG-TERM OUTCOMES AFTER RADICAL PROSTATECTOMY: A 25-YEAR SINGLE INSTITUTION EXPERIENCE (2015) (0)
What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series (2021) (0)
Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy (2020) (0)
Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma (2021) (0)
In-Home Intravesical Therapy: The Future of Non-muscle Invasive Bladder Cancer Care Delivery?. Letter. (2023) (0)
MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS (2016) (0)
Patient reported quality of life measures 15 years post-radical prostatectomy: A matched comparison of open retropubic and robot assisted techniques (2020) (0)
MP63-20 DEVELOPMENT AND EXTERNAL VALIDATION OF A PATHOLOGICAL NODAL STAGING SCORE FOR PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA (2015) (0)
MP64-08 CONTEMPORARY UTILIZATION OF THE SSIGN SCORE (2016) (0)
IMPACT OF DISCORDANCE BETWEEN CLINICAL AND PATHOLOGICAL GLEASON SCORE ON SURVIVAL FOLLOWING RADICAL PROSTATECTOMY (2008) (0)
MP86-17 SCREENING POSTOPERATIVE HEMOGLOBIN AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: FREQUENTLY UTILIZED, BUT NECESSARY? (2018) (0)
758 THE CHANGING “LANDSCAPE” OF CLINICAL T3 PROSTATE CANCER (2012) (0)
PD12-09 EFFICIENCY AND SATISFACTION OF VIDEO-VISITS IS EQUIVALENT TO AN OFFICE VISIT: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY IN UROLOGY (2015) (0)
Abstract P190: Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma (2021) (0)
Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series (2020) (0)
MP37-17 CHANGING PATTERNS AND PREDICTORS OF SALVAGE RADIATION THERAPY USE OVER TIME IN PATIENTS TREATED FOR POST-PROSTATECTOMY BIOCHEMICAL RECURRENCE: A TREND ANALYSIS OVER A 20-YEAR PERIOD FROM A MULTI-INSTITUTIONAL SERIES (2020) (0)
MP27-19 COMPARATIVE OUT-OF-POCKET COSTS OF TREATMENT OPTIONS IN PRIVATELY INSURED PATIENTS WITH ADVANCED PROSTATE CANCER (2022) (0)
775 THE MTOR PATHWAY IMPACTS PROLIFERATION AND CHEMOSENSITIVITY OF UROTHELIAL CARCINOMA CELLS IN VITRO AND IS HIGHLY EXPRESSED IN A SUBSET OF HUMAN BLADDER CANCERS (2010) (0)
More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes after salvage radiotherapy for rising PSA after surgery: A long-term, multi-institutional analysis (2017) (0)
ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST‐PROSTATECTOMY RADIATION THERAPY: A LONG‐TERM MULTI‐INSTITUTIONAL ANALYSIS: PD72‐10 (2017) (0)
Platinum Priority – Review – Kidney Cancer (2018) (0)
MP01-02 EFFICACY OF INTRAOPERATIVE TRANEXAMIC ACID INFUSION FOR REDUCING BLOOD TRANSFUSION DURING RADICAL CYSTECTOMY (2016) (0)
IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG‐TERM MULTI‐INSTITUTIONAL ANALYSIS: PD51‐02 (2017) (0)
Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy. (2014) (0)
Identifying Current Trends in the Urologic Oncology Workforce—Does Completion of Fellowship Significantly Change Future Practice? (2019) (0)
Predictors and outcomes for late recurrence of renal cell carcinoma. (2011) (0)
PD41-07 EXAMINING THE MD ANDERSON RISK CRITERIA FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: ARE LOW RISK PATIENTS HARMED WITH UPFRONT CYSTECTOMY? (2018) (0)
The effect of adjuvant chemotherapy for patients with adverse pathology after neoadjuvant chemotherapy for muscle invasive bladder cancer. (2017) (0)
Positive predictive value of mpmri in men under active surveillance: Can the biopsy history influence radiological assessment? (2021) (0)
537 NEPHROMETRY SCORE INTEROBSERVER AGREEMENT IS ROBUST ACROSS SPECIALTIES AND LEVELS OF TRAINING (2011) (0)
MP47-05 THE ASSOCIATION OF TRAINEE INVOLVEMENT IN RADICAL CYSTECTOMY WITH PERIOPERATIVE AND ONCOLOGIC OUTCOMES (2020) (0)
PD10-05 PERIOPERATIVE BLOOD TRANSFUSION IS ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM AFTER RADICAL CYSTECTOMY (2022) (0)
MP34-12 THE ROLE OF SALVAGE LYMPH NODE DISSECTION IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A SINGLE CENTER EXPERIENCE (2019) (0)
Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer (2009) (0)
Predicting survival after radical cystectomy: Validation of the SPARC score. (2015) (0)
International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. (2022) (0)
PD31-01 SURVEILLANCE STRATEGIES IN BLADDER CANCER FOLLOWING RADICAL CYSTECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015) (0)
MP56-20 CLINICOPATHOLOGIC OUTCOMES OF PATIENTS WITH CARCINOMA IN SITU UNDERGOING RADICAL CYSTECTOMY (2014) (0)
MP67-02 ABCDE: A RISK SCORE FOR PROLONGED HOSPITALIZATION AMONG PATIENTS UNDERGOING RADICAL CYSTECTOMY (2015) (0)
Reply by Authors. (2020) (0)
underutilized (reference 25 from paper). Hopefully, those who have been awaiting data from randomized trials before changing practice patterns will read these results and expand the application of nephron-sparing surgery. (2008) (0)
FUNCTIONAL AND ONCOLOGIC OUTCOMES AFTER ORTHOTOPIC URINARY DIVERSION IN WOMEN (2008) (0)
Phase I/II trial of interferon {alpha}2b and ATRA-IV in the treatment of patients with advanced renal cancer (2005) (0)
MP48-09 TOXICITY PROFILE OF IMMEDIATE POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES (2022) (0)
Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis (2023) (0)
The probability of indolent versus aggressive histology based on renal tumor size: Implications for surveillance and treatment. (2018) (0)
1088 PREDICTORS AND OUTCOMES OF LATE RECURRENCE FROM RENAL CELL CARCINOMA FOLLOWING SURGICAL RESECTION (2011) (0)
Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series (2020) (0)
Assessing the Impact of Hospital Dismissal Summary Readability on Patient Outcomes Following Prostatectomy. (2021) (0)
The effect of the diagnosis and treatment of lower urinary tract symptoms (LUTS) on the diagnosis of prostate cancer in a population cohort with 20-year follow-up. (2012) (0)
1904 THE IMPACT OF NON-CLEAR CELL HISTOLOGY ON OUTCOME FOR PATIENT WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS (2013) (0)
730 ASSOCIATION OF MICROVASCULAR AND CAPILLARY-LYMPHATIC INVASION WITH OUTCOME FOR PATIENTS WITH RENAL CELL CARCINOMA FOLLOWING NEPHRECTOMY (2013) (0)
MP33-08 DEEP LEARNING RENAL VOLUME ANALYSIS TO PREDICT LONG-TERM RENAL FUNCTION AFTER PARTIAL AND RADICAL NEPHRECTOMY (2022) (0)
MP29-12 COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT (2019) (0)
MP69-08 AN ANALYSIS OF THE MORBIDITY OF LIMITED, EXTENDED, AND SUPER-EXTENDED PELVIC LYMPHADENECTOMY TEMPLATES DURING RADICAL PROSTATECTOMY (2016) (0)
MP70-12 IS CONCOMITANT HEPATIC RESECTION FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA AT THE TIME OF NEPHRECTOMY SAFE? A MATCHED COHORT STUDY (2015) (0)
MP80-05 NERVE SPARING DURING RADICAL PROSTATECTOMY DOES NOT ADVERSELY IMPACT MARGIN STATUS, COMPLICATIONS, OR LONG-TERM ONCOLOGIC OUTCOMES (2016) (0)
151 Association of the expression of T-cell coregulatory proteins with clinical outcomes in patients with urothelial carcinoma of the bladder (2013) (0)
Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in PT3N0 prostate cancer patients treated with radical prostatectomy: results of amulti-institutional series (2016) (0)
MP41-20 THE ASSOCIATION OF PREOPERATIVE ASPIRIN USE WITH SURVIVAL FOLLOWING RADICAL CYSTECTOMY (2018) (0)
MP55-15 SARCOPENIA IS ASSOCIATED WITH INCREASED CANCER-SPECIFIC AND ALL-CAUSE MORTALITY AMONG PATIENTS WITH BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY (2014) (0)
395 ASSOCIATION OF HER2 STATUS WITH CLINICOPATHOLOGIC OUTCOMES IN MICROPAPILLARY UROTHELIAL CARCINOMA (2013) (0)
MP42-19 TIME TRENDS IN CLINICOPATHOLOGIC DEMOGRAPHICS OF MEN WITH HIGH-RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY (2014) (0)
CREATION OF A PREDICTION TOOL FOR RENAL FUNCTION AFTER PARTIAL AND RADICAL NEPHRECTOMY: PERSONALIZING DECISION‐MAKING FOR RENAL CANCER SURGERY: PD66‐07 (2017) (0)
Creation of a tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. (2018) (0)
Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy (2022) (0)
AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy? (2014) (0)
PD57-07 RAPID PATIENT DERIVED XENOGRAFTS THAT CONSIDER TUMOR HETEROGENEITY FOR PREDICTION OF CANCER IMMUNOTHERAPY RESPONSES IN METASTATIC RENAL CELL CARCINOMA (2018) (0)
MP39-13 COST-EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY REGIMENS PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER (2022) (0)
PREDICTING RENAL CELL CARCINOMA PROGRESSION AFTER SURGERY: MP72‐01 (2017) (0)
MP21-03 CD-70 BLOCKADE AS A NOVEL IMMUNOTHERAPY FOR THE TREATMENT OF CLEAR-CELL RENAL CELL CARCINOMA (2019) (0)
COMPETING CAUSES OF MORTALITY IN PATIENTS WITH T1B RENAL CELL CARCINOMA: ADDITIONAL EVIDENCE TO EXPAND THE INDICATIONS FOR NEPHRON SPARING SURGERY (2009) (0)
PD09-02 ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL (2021) (0)
522 NEOADJUVANT ACCELERATED MVAC IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: A MULTI-INSTITUTIONAL PROSPECTIVELY ACCRUED COHORT (2013) (0)
MP58-09 TRUE LOCAL RECURRENCE FOLLOWING PARTIAL NEPHRECTOMY (2023) (0)
Mp70-14 The Oncologic Impact Of Positive Vascular Wall Surgical Margins In Patients With Renal Cell Carcinoma And Venous Tumor Thrombus Undergoing Nephrectomy (2015) (0)
PD18-07 QUANTIFYING THE “EYEBALL TEST”: PREOPERATIVE PREDICTORS OF PROLONGED LENGTH OF STAY AFTER RADICAL CYSTECTOMY (2014) (0)
The effect of the diagnosis and treatment of lower urinary tract symptoms (LUTS) on the diagnosis of prostate cancer in a population cohort with 20-year follow-up. (2012) (0)
390 THE IMPACT OF MIXED HISTOLOGAL FEATURES ON SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA (2012) (0)
PD57-02 CREATION OF A TISSUE EXPRESSION BIOMARKER-AUGMENTED PROGNOSTIC MODEL FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2018) (0)
SURGICAL MANAGEMENT OF UROTHELIAL CARCINOMA IN PATIENTS WITH UPPER TRACT AND LOWER TRACT UROTHELIAL CARCINOMA: IMPACT OF SURGICAL SEQUENCE: MP78‐19 (2017) (0)
Discovery of a genomic classifier for predicting clinically aggressive luminal bladder tumors with higher rates of pathological upstaging (2020) (0)
760: Expression of TNF-Related Apoptosis Inducing Ligand (TRAIL) is Reduced in Bladder Tumor Tissue but may be Restored in Bladder Cancer Cell Lines by Treatment with Retinoic Acid (2005) (0)
RENAL MASS SIZE AND SYNCHRONOUS METASTATIC DISEASE IN RENAL CELL CARCINOMA: AN ANALYSIS OF THE NATIONAL CANCER DATABASE: MP22‐15 (2017) (0)
Survival outcomes and salvage treatments for local bladder cancer recurrences following radical cystectomy (2019) (0)
MP33-18 SURGICAL AND ONCOLOGIC OUTCOMES OF SURGERY IN EARLY METASTATIC SEMINOMA: MULTI-INSTITUTIONAL RETROSPECTIVE STUDY (2023) (0)
300 CLINICAL STAGE PREDICTS CANCER SPECIFIC SURVIVAL AFTER RADICAL PROSTATECTOMY PRIOR TO AND DURING PSA ERA (2011) (0)
SUO CURRICULUM OUTLINE (2013 Update) Topic Author (2013) (0)
MP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMA (2015) (0)
1902 PROGNOSTIC SIGNIFICANCE OF MEASURED DEPTH OF INVASION OF BLADDER UROTHELIAL CARCINOMA VERSUS 2010 AMERICAN JOINT COMMITTEE ON CANCER (AJCC) PT CLASSIFICATION (2012) (0)
MP55-13 INTRAOPERATIVE BLOOD TRANSFUSION DURING RADICAL CYSTECTOMY INCREASES THE RISK OF DEATH FROM BLADDER CANCER COMPARED TO POSTOPERATIVE TRANSFUSION (2014) (0)
Defining Biochemical Failure following Salvage Radiotherapy (2009) (0)
Bladder Cancer: Invasive VMP72-11 OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR PLASMACYTOID UROTHELIAL CARCINOMA: DEFINING THE NEED FOR IMPROVED LOCAL CANCER CONTROL (2015) (0)
PD04-04 OPTIMIZING PATIENT SELECTION FOR CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA (2016) (0)
Survival patterns based on site-specific visceral metastasis in metastatic prostate cancer patients: Are outcomes of visceral metastases the same? (2023) (0)
892 OUTCOMES OF PATIENTS WITH PATHOLOGIC LYMPH NODE METASTASES TREATED WITH RADICAL PROSTATECTOMY; THE PROGNOSTIC VALUE OF PREOPERATIVE RADIOGRAPHIC LYMPHADENOPATHY (2011) (0)
431 External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy (2016) (0)
THE ASSOCIATION OF TRAINEE INVOLVEMENT IN RADICAL CYSTECTOMY WITH PERIOPERATIVE AND ONCOLOGIC OUTCOMES (2022) (0)
Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy. (2014) (0)
UTILIZATION OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA IN A CONTEMPORARY TERTIARY CARE COHORT: MP10‐16 (2017) (0)
PD12-09 CHARACTERIZATION OF INFECTION RISK AFTER RADICAL CYSTECTOMY: RESULTS FROM THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (2016) (0)
PD15-06 HETEROGENEITY OF RISK WITHIN GLEASON 8 AND 9 PROSTATE CANCER (2014) (0)
MP37-11 ASSOCIATION BETWEEN THE EXTENT OF LYMPH NODE DISSECTION AND SEVERE TOXICITY IN MEN WITH PROSTATE CANCER TREATED WITH POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES (2020) (0)
1768 IMPACT OF MICROPAPILLARY UROTHELIAL CARCINOMA VARIANT HISTOLOGY ON SURVIVAL AFTER RADICAL CYSTECTOMY: A MULTI-INSTITUTIONAL ANALYSIS (2013) (0)
MP40-18 LONG-TERM ONCOLOGICAL OUTCOMES FOLLOWING RADICAL PROSTATECTOMY FOR CLINICAL T1A AND T1B PROSTATE CANCER (2016) (0)
MP70-06 WITHDRAWN: SALVAGE RADIATION THERAPY IS ASSOCIATED WITH DECREASED RISK OF METASTASES AND DEATH FROM PROSTATE CANCER AMONG PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2014) (0)
MP18-16 INDIVIDUAL DATA META-ANALYSIS OF DISCRIMINATION OF THE STATISTICAL MODEL BASED ON THE FOUR KALLIKREIN PANEL ASSOCIATED WITH THE INCLUSION OF PROSTATE VOLUME (2019) (0)
Editorial: Neoadjuvant systemic therapies in bladder, kidney, and prostate cancers (2022) (0)
1212 ROBOTIC RADICAL PROSTATECTOMY DECREASES THE INCIDENCE AND MORBIDITY OF SURGICAL SITE INFECTIONS (2011) (0)
PD03-11 TOLERABILITY AND ADVERSE EFFECT PROFILE OF EVEROLIMUS IN PATIENTS WITH SPORADIC ANGIOMYOLIPOMAS (2019) (0)
CUAJ – Original Research Mason et al Link between adiposity and BCR after prostatectomy Examining the association between adiposity and biochemical recurrence after radical prostatectomy (2018) (0)
The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study (2018) (0)
MP03-05 RADIOGRAPHIC SIZE OF RETROPERITONEAL LYMPH NODES PREDICTS PATHOLOGIC NODAL INVOLVEMENT FOR PATIENTS UNDERGOING RADICAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: DEVELOPMENT OF A RISK PREDICTION MODEL (2016) (0)
PD15-04 THERE IS NO WAY TO COMPENSATE FOR A NON-TIMELY USE OF SALVAGE RADIATION THERAPY IN MEN WITH RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY (2019) (0)
MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY (2019) (0)
Trends in minimally invasive surgery for the kidney and prostate--when are you doing the patient a disservice by not referring? (2012) (0)
SURVIVAL AMONG FEMALE URETHRAL CANCER PATIENTS 2004‐2013, A NATIONAL CANCER DATABASE ANALYSIS: PD49‐11 (2017) (0)
PRACTICE PATTERNS AND SURVIVAL FOR PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER: DOES REAL WORLD PRACTICE PARALLEL CLINICAL TRIAL OUTCOMES?: MP34‐02 (2017) (0)
1700 THE IMPACT OF RADICAL CYSTECTOMY ON ELIGIBILITY TO RECEIVE PERIOPERATIVE CHEMOTHERAPY BASED ON RENAL FUNCTION (2010) (0)
9and Significance of Micrometastases (2010) (0)
361 RISK FACTORS AND OUTCOMES OF URETHRAL RECURRENCE FOLLOWING RADICAL CYSTECTOMY (2011) (0)
PD43-04 COMPARING THE 8-YEAR ONCOLOGIC OUTCOMES OF OPEN AND ROBOT-ASSISTED RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER (2015) (0)
1294 ELIGIBILITY FOR NEOADJUVANT/ADJUVANT CISPLATIN-BASED CHEMOTHERAPY AMONG RADICAL CYSTECTOMY PATIENTS (2013) (0)
Likelihood of high volume renal surgeons to offer elective partial nephrectomy in high complexity tumors as classified by the nephrometry scoring system. (2011) (0)
PD16-12 PROGNOSTIC EVALUATION OF PERINEPHRIC FAT, RENAL SINUS FAT, AND RENAL VEIN INVASION FOR PATIENTS WITH PATHOLOGIC STAGE T3A RENAL CELL CARCINOMA (2018) (0)
Microscopic Hematuria: Diagnosis Is Only Half the Battle. (2019) (0)
Perioperative morbidity of surgical metastasectomy for renal cell carcinoma: An international multicenter study (2022) (0)
PD27-03 ONCOLOGIC SURVEILLANCE FOLLOWING RADICAL CYSTECTOMY: AN INDIVIDUALIZED RISK-BASED APPROACH. (2016) (0)
Letters to the Editor/Errata Re: Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis (2013) (0)
MP84-17 CONTEMPORARY PRACTICE PATTERNS FOR PATIENTS WITH STAGE IV RENAL CELL CARCINOMA: A NATIONAL CANCER DATABASE ANALYSIS (2015) (0)
Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-Analysis. (2023) (0)
MP26-18 PROGNOSTIC FEATURES AND MICROBIAL DISTRIBUTION OF URINARY TRACT INFECTION FOLLOWING RADICAL CYSTECTOMY (2016) (0)
126 Prognostic model for predicting survival in patients with disease recurrence following radical cystectomy (2014) (0)
A SEER-Medicare based quality score for patients with synchronous and metachronous metastatic upper tract urothelial carcinoma and its association with cost of care and survival. (2023) (0)
What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study (2018) (0)
PD56-03 CONTEMPORARY PERIOPERATIVE COMPLICATIONS OF SURGERY FOR RENAL CELL CARCINOMA WITH INFERIOR VENA CAVA THROMBECTOMY (2022) (0)
MP48-09 UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY: A RISK-ADAPTED SCORING MODEL FOR STRATIFYING SURVEILLANCE INTENSITY (2021) (0)
MP20-19 SAFETY AND EFFICACY OF INTRAVESICAL ALUM FOR INTRACTABLE HEMORRHAGIC CYSTITIS: A CONTEMPORARY EVALUATION (2015) (0)
Cytogenetics of Spermatocytic Tumors with a Discussion of Gain of Chromosome 12p in "Anaplastic Variants". (2022) (0)
MP59-04 PREOPERATIVE NEUTROPHIL LYMPHOCYTE RATIO IS AN INDEPENDENT PREDICTOR OF CANCER SPECIFIC SURVIVAL IN PATIENTS WITH NONMETASTATIC CLEAR CELL RENAL CARCINOMA UNDERGOING RADICAL NEPHRECTOMY (2014) (0)
680: Multivariate Analysis of Cancer Specific Survival and Overall Survival in Patients with High-Grade Prostate Cancer (2005) (0)
26 ROUTINE ADRENALECTOMY IS UNNECESSARY DURING SURGERY FOR RENAL CELL CARCINOMA (RCC) - EVEN FOR LARGE AND/OR UPPER POLE TUMORS (2010) (0)
236 RISK STRATIFICATION OF PATIENTS WITH EXTRACAPSULAR EXTENSION (PT3AN0) AT RADICAL PROSTATECTOMY: IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT THERAPY (2013) (0)
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer? (2021) (0)
MP73-13 MULTI-INSTITUTIONAL OUTCOMES OF PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WHO UNDERGO RADICAL CYSTECTOMY AFTER BCG AND SUBSEQUENT SALVAGE INTRAVESICAL THERAPY (2020) (0)
Mapping prostate cancer (CaP) recurrence after prostatectomy with c-11 choline PET/CT and 3T pelvic MRI in the contemporary era. (2016) (0)
IMPACT OF FAMILY HISTORY ON OUTCOME IN RENAL CELL CARCINOMA (2008) (0)
ONCOLOGIC OUTCOMES FOR PATIENTS WITH RESIDUAL CANCER AT CYSTECTOMY FOLLOWING PREOPERATIVE CHEMOTHERAPY: A PATHOLOGIC STAGE‐MATCHED COMPARATIVE ANALYSIS: MP34‐03 (2017) (0)
Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international multi-institutional study (2016) (0)
PD33-03 IS ANGIOTENSIN SYSTEM INHIBITOR USE ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH LOCALIZED CLEAR CELL RCC? (2022) (0)
Assessing the need for and the optimal duration of hormonal therapy in association with post-prostatectomy radiation therapy: Results from a multi-institutional study (2018) (0)
Letters to the Editor/Errata Re: Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis (2013) (0)
SURVIVAL AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PSA PERSISTENCE: THE IMPACT OF COMPETING CAUSES OF MORTALITY: PD51‐10 (2017) (0)
Biological and prognostic implications of biopsy upgrading for high‐grade upper tract urothelial carcinoma at nephroureterectomy (2022) (0)
THE EFFECT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH ADVERSE PATHOLOGY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE‐INVASIVE BLADDER CANCER: MP34‐14 (2017) (0)
1907: The Role of Inferior Vena Caval Interruption During Radical Nephrectomy and Tumor Thrombectomy (2007) (0)
MP42-13 ASSOCIATION OF PARTIAL VERSUS RADICAL NEPHRECTOMY WITH SUBSEQUENT HYPERTENSION RISK FOLLOWING RENAL TUMOR RESECTION (2019) (0)
140 Assessment of differences in tumor mutational burden identified on liquid biopsy in 16,870 patients newly diagnosed with metastatic cancer (2022) (0)
MP69-09 A SEER-MEDICARE BASED QUALITY SCORE FOR PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA AND ITS ASSOCIATION WITH COST AND SURVIVAL (2023) (0)
PD15-07 THE LIMITED ROLE OF CLINICAL VARIABLES AS PREDICTORS OF PATHOLOGIC DOWNSTAGING FROM NEOADJUVANT CHEMOTHERAPY: HIGHLIGHTING THE NEED FOR GENOMIC PREDICTORS (2018) (0)
MP54-12 DIABETES MELLITUS IS ASSOCIATED WITH AN INCREASED RISK OF CANCER-SPECIFIC MORTALITY AMONG PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY (2014) (0)
OP3-07 HOW EFFECTIVELY DO EAU AND NCCN SURVEILLANCE GUIDELINES CAPTURE RECURRENCES FOLLOWING RADICAL CYSTECTOMY? (2014) (0)
MP60-05 WHEN CAN ONCOLOGIC SURVEILLANCE FOLLOWING RADICAL CYSTECTOMY BE SAFELY DISCONTINUED? (2014) (0)
MP39-01 GEOGRAPHIC DISPARITIES IN UROLOGIC CANCER MORTALITY: WHERE SHOULD WE TEST TELEMEDICINE INTERVENTIONS? (2019) (0)
Editorial comment. (2010) (0)
MP03-11 RETROPERITONEAL LYMPH NODE DISSECTION IS NOT ASSOCIATED WITH IMPROVED SURVIVAL AMONG PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: A PROPENSITY-SCORE BASED ANALYSIS (2016) (0)
MP39-04 THE IMPACT OF MEDICARE LOW-INCOME SUBSIDY ON ACCESS TO TREATMENT, TREATMENT CHOICE, AND ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTATIC PROSTATE CANCER (2023) (0)
Standard vs extended pelvic lymph node dissection: Peri-operative complications and survival outcomes following radical cystectomy (2019) (0)
IMPACT OF OBESITY ON PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: MP93‐16 (2017) (0)
924 Comparative performance of comorbidity indices for estimating perioperative and 5-year all-cause mortality following radical cystectomy (2013) (0)
Oncology: Adrenal/Renal/Upper Tract/Bladder Association of Microvascular and Capillary-Lymphatic Invasion with Outcome in Patients with Renal Cell Carcinoma (2013) (0)
Renal ablation of TT1atumors in the elderly population (2014) (0)
MP42-12 END-STAGE KIDNEY DISEASE AFTER PARTIAL AND RADICAL NEPHRECTOMY AMONG PATIENTS WITH SEVERE CHRONIC KIDNEY DISEASE (2021) (0)
THE ASSOCIATION OF AGE WITH PERIOPERATIVE AND CLINICOPATHOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR NON‐MUSCLE INVASIVE BLADDER CANCER: MP15‐16 (2017) (0)
MP58-02 EVALUATION OF AMERICAN UROLOGICAL ASSOCIATION RENAL CELL CARCINOMA RISK GROUPS FOR CHROMOPHOBE RENAL CELL CARCINOMA (2023) (0)
THE IMPACT OF THE PSA ERA ON THE INCIDENCE AND PREDICTORS OF POSITIVE SURGICAL MARGINS AT RADICAL PROSTATECTOMY (2009) (0)
Screening Postoperative Hemoglobin after Robot-Assisted Radical Prostatectomy—Frequently Used, but Is It Necessary? (2019) (0)
Progression of Chronic Kidney Disease Following Radical and Partial Nephrectomy. (2022) (0)
ASSOCIATION OF PERIOPERATIVE VENOUS THROMBOEMBOLISM WITH LONG‐TERM ONCOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY: MP10‐11 (2017) (0)
Financial toxicity and coping mechanisms in patients with metastatic prostate cancer: A pilot study. (2023) (0)
MP33-03 COMPARATIVE COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR STAGE IIA SEMINOMA: INSIGHTS FROM THE SEMS TRIAL (2023) (0)
Survival patterns based on site-specific visceral metastasis in patients with metastatic prostate cancer: Are outcomes of visceral metastases the same? (2023) (0)
MP08-14 EVALUATION OF THE UROVYSION™ TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER (2018) (0)
Safety and efficacy of extended-duration thromboembolic prophylaxis following radical cystectomy. (2016) (0)
Surgery of the adrenal (2006) (0)
Efficacy of RestoreX Post Prostatectomy: Open-label Phase of a Randomized, Controlled Trial. (2023) (0)
Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE). (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stephen Anthony Boorjian?

Stephen Anthony Boorjian is affiliated with the following schools:

University of Kentucky
Michigan State University
Thomas Jefferson University